top of page
e7df9f_f41f8d6811fd477bbfa37b8fe49c8b7e~mv2_edited.png

Product Candidates

DT109

Non clinical pharmacology work for DT-109 has been completed (Publications). DT109 has shown efficacy for the treatment of MASH in mouse and nonhuman primates and also anti-atherosclerotic benefits. Nonclinical IND enabling studies are in progress.

DT678

The IND for DT678 has been filed in the US and China and Phase 1 SAD, MAD, Food Effect and Drug-drug interaction studies have been completed. Long term chronic toxicology studies have been completed for DT678 and a Phase 2 study is planned.

bottom of page